DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma

Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study

The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.

Inclusion Criteria:

• Age >18 years at time of consent
• Histopathologically confirmed diagnosis of renal cell carcinoma
• Received standardized treatment of renal cell carcinoma
• Interval between the last standardized treatment and DC/CIK treatment ≥ 4weeks
• KPS (Karnofsky performance scale) >60
• Patient's written informed consent
• Predicted survival >3 months
• No severe viral or bacterial infections

Exclusion Criteria:

• Receiving chemotherapy, radiotherapy or other therapy
• Patients with other malignancies and infectious diseases
• Pregnant and breast-feeding patient
• Currently participating in another clinical trial
• Unfit for participating in this clinical trial in investigators' opinions